Key Protective Proteins Affect the Prognosis of Patients with Type 2 Diabetes Isolated Recently

Recently, scientists at Trinity College Dublin have identified for the first time a family of proteins that may be directly linked to lower blood sugar levels in obese patients with type 2 diabetes. The results of this study show that patients with type 2 diabetes who have higher levels of IL-36 cytokines tend to have lower blood glucose levels, suggesting that these proteins (IL-36) may better control blood glucose levels and disease progression in patients.

IL-36 is a member of the interleukin-1 protein family, which plays a central role in the development of obesity-related diseases. Now researchers have linked the protective effects of these proteins to their ability to alter the host’s gut microbiome; obesity tends to trigger increased levels of fatty acids and inflammation that induce insulin tolerance, and when the body is tolerant to the resulting insulin, it triggers the build-up of blood sugar that eventually triggers the development of type 2 diabetes.

Nowadays obesity is considered a global epidemic, and it is directly related to the occurrence of a variety of diseases, including metabolic disorders, such as diabetes, stroke and many types of cancer; the World Health Organization says that the global prevalence of obesity has more than doubled since 1980, and in Ireland, 854, 165 adults over the age of 40 are at increased risk of type 2 diabetes, and in the Irish health care system, the economic burden of diabetes is a major challenge for the government.

Given the magnitude and global impact of the obesity problem, current approaches aimed at reversing obesity-induced diseases may not be sufficient. Researchers believe that there is an urgent need to gain insight into the mechanisms of obesity-related diseases. “This study sheds light on the importance of the interleukin-1 protein family as mediators of metabolic health and disease,” said investigator Patrick Walsh. “Later, we hope to further understand the molecular mechanisms by which IL-36 cytokines affect the development of a variety of human diseases, thus helping to develop novel therapies for a variety of diseases.”